Medication info
Dangijanujeong 25 Milligrams (Sitagliptin Hydrochloride Hydrate)

Dangijanujeong 25 Milligrams (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
Myeongmun Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablets
Packaging
30 tablets/box [10 tablets/PTPX3]
Approval status
Active

MFDS item code 202004043 · Approved 2020.05.29 · Insurance code 649807900

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, with a maximum daily dose of 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. The dose for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) is 50 mg once daily. 4. The dose for patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) is 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Myeongmun Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. Initially, it is administered as monotherapy, and if there is no prior experience with diabetes medication and sufficient blood sugar control cannot be achieved with monotherapy, it may be combined with metformin. Additionally, if blood sugar control is insufficient with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is also prescribed in combination. In cases where blood sugar control is difficult with multiple medication combinations, this medication is added for more effective blood sugar management. It is utilized to improve blood sugar control in various treatment situations.

Dosage and Administration

Adult dosage

This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, with a maximum daily dose of 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. The dose for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) is 50 mg once daily. 4. The dose for patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) is 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, so if skin rash, itching, difficulty breathing, or other symptoms occur after taking the medication, seek medical attention immediately. This medication can cause serious inflammation of the pancreas known as pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting occur, discontinue use immediately and consult a healthcare professional. Do not use this medication in patients with type 1 diabetes or diabetic ketoacidosis. Patients allergic to this medication or its components should avoid taking it. Patients with impaired kidney function may accumulate the medication in the body, so dose adjustment is necessary and should be taken under a physician's guidance. Hypoglycemia symptoms may occur during the use of this medication, so especially when taken with insulin or sulfonylureas, blood sugar levels should be monitored closely. If severe joint pain or blisters on the skin develop, inform a physician immediately and stop taking the medication. Pregnant or breastfeeding women are advised not to take this medication, and its safety in children and adolescents has not been established. The elderly may have reduced kidney function, so kidney function should be assessed before taking the medication, and dose adjustment may be necessary. In case of overdose, seek medical attention immediately for appropriate treatment; this medication can be partially removed through dialysis. The risk of hypoglycemia may increase when used with other blood sugar-lowering agents, so it is important to consult with a physician about other medications being taken. Additionally, this medication may interact with some other drugs, so be sure to inform healthcare professionals about any other medications you are currently taking.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 28 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • increased liver enzyme levels
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. This storage helps maintain the medication's effectiveness.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablets

Package unit

30 tablets/box [10 tablets/PTPX3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.